PrecisemAb Biotech is pleased to have contributed to the early-stage Antibody Lock design of GNX201 with GlycoNex Inc., and we sincerely congratulate GlycoNex on entering a new milestone through its collaboration with Nippon Kayaku Co., Ltd. to advance the GNX201-ADC development program.
GlycoNex has built strong expertise in glycan-targeting antibodies and tumor-associated glycan antigen development. GNX201-ADC combines Antibody Lock design with an ADC development strategy, representing an innovative approach to balancing efficacy, safety, and disease selectivity in next-generation antibody therapeutics.
For PrecisemAb Biotech, safety in antibody drug development is not only a matter of managing side effects. It is a key factor that directly affects clinical progression, development success, and overall developability. Many promising antibodies are not limited by lack of efficacy, but by safety constraints and narrow therapeutic windows that prevent them from advancing further in development. This is why conditional activation strategies are increasingly becoming an important direction in antibody drug design.
PrecisemAb Biotech remains dedicated to advancing its Antibody Lock technology platform and expanding its applications across different antibody therapeutic formats. Our goal is to enable antibody therapeutics to act more selectively in disease-associated microenvironments while reducing potential effects on normal tissues. We are encouraged to see growing adoption and discussion of Antibody Lock-related designs in the field, and we look forward to continuing collaborations with biotech and pharmaceutical partners worldwide to bring safer and more disease-selective antibody therapeutics toward clinical translation and global markets.
News: PR NEWS